Vanda Moves Ahead With Development Of Iloperidone, VEC-162
This article was originally published in The Pink Sheet Daily
Executive Summary
Following an end-of-Phase II meeting with FDA, Vanda plans to initiate a Phase III study of VEC-162 in sleep disorders in third quarter.
You may also be interested in...
Vanda Reports Strong Phase III Data For Sleep Disorder Candidate In Chronic Insomnia
VEC-162 also being tested in transient insomnia, circadian rhythm sleep disorders and mood disorders.
Vanda Reports Strong Phase III Data For Sleep Disorder Candidate In Chronic Insomnia
VEC-162 also being tested in transient insomnia, circadian rhythm sleep disorders and mood disorders.
Vanda Atypical Antipsychotic Shows Apparent Genetic Response In Phase III
Study of iloperidone in schizophrenics meets its primary endpoint and also included a genetic profiling evaluation.